Stock A049960 CELL BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cell Biotech Co., Ltd.

Equities

A049960

KR7049960008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
13,400 KRW -0.15% Intraday chart for Cell Biotech Co., Ltd. +6.94% +19.43%
2023 Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,10,487 1,37,400 1,66,285 1,33,300 86,918 76,789
Enterprise Value (EV) 1 1,48,321 79,102 1,12,743 76,293 22,508 8,012
P/E ratio 10.9 x 19.4 x 52.3 x 12.8 x 10.6 x 12.2 x
Yield 2.14% 3.17% 1.91% 2.39% 3.54% 4.01%
Capitalization / Revenue 3.37 x 2.99 x 3.65 x 2.84 x 1.72 x 1.43 x
EV / Revenue 2.37 x 1.72 x 2.47 x 1.63 x 0.45 x 0.15 x
EV / EBITDA 6.3 x 9.4 x 15.3 x 6.91 x 2.32 x 1.31 x
EV / FCF 262 x 29.1 x 36.9 x 8.29 x 4.06 x -23.9 x
FCF Yield 0.38% 3.44% 2.71% 12.1% 24.6% -4.19%
Price to Book 1.99 x 1.36 x 1.67 x 1.25 x 0.8 x 0.69 x
Nbr of stocks (in thousands) 7,504 7,251 7,076 7,072 6,844 6,844
Reference price 2 28,050 18,950 23,500 18,850 12,700 11,220
Announcement Date 13/03/19 18/03/20 17/03/21 22/03/22 15/03/23 19/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 62,544 45,960 45,582 46,873 50,526 53,787
EBITDA 1 23,547 8,415 7,352 11,046 9,689 6,100
EBIT 1 21,675 5,795 3,667 7,257 6,051 2,195
Operating Margin 34.66% 12.61% 8.05% 15.48% 11.98% 4.08%
Earnings before Tax (EBT) 1 23,861 8,307 2,402 12,090 10,172 6,880
Net income 1 19,384 7,231 3,189 10,383 8,281 6,304
Net margin 30.99% 15.73% 7% 22.15% 16.39% 11.72%
EPS 2 2,583 975.9 449.6 1,468 1,201 921.0
Free Cash Flow 1 565.7 2,721 3,057 9,207 5,547 -335.6
FCF margin 0.9% 5.92% 6.71% 19.64% 10.98% -0.62%
FCF Conversion (EBITDA) 2.4% 32.34% 41.58% 83.35% 57.25% -
FCF Conversion (Net income) 2.92% 37.63% 95.86% 88.67% 66.99% -
Dividend per Share 2 600.0 600.0 450.0 450.0 450.0 450.0
Announcement Date 13/03/19 18/03/20 17/03/21 22/03/22 15/03/23 19/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 62,166 58,299 53,542 57,007 64,409 68,777
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 566 2,721 3,057 9,207 5,547 -336
ROE (net income / shareholders' equity) 19.8% 6.91% 3.13% 10% 7.71% 5.73%
ROA (Net income/ Total Assets) 13% 3.29% 2.15% 4.16% 3.31% 1.18%
Assets 1 1,49,190 2,19,984 1,48,611 2,49,757 2,50,375 5,36,350
Book Value Per Share 2 14,076 13,983 14,094 15,087 15,794 16,348
Cash Flow per Share 2 1,778 1,272 1,353 1,394 1,236 1,152
Capex 1 7,109 9,468 3,079 849 2,368 1,552
Capex / Sales 11.37% 20.6% 6.75% 1.81% 4.69% 2.88%
Announcement Date 13/03/19 18/03/20 17/03/21 22/03/22 15/03/23 19/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CELL BIOTECH CO., LTD. Stock Cell Biotech Co., Ltd.
+19.43% 6.64Cr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.44% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.94% 11TCr
ARGENX SE Stock argenx SE
+19.62% 2.57TCr
BIONTECH SE Stock BioNTech SE
-25.37% 1.9TCr
GENMAB A/S Stock Genmab A/S
-20.21% 1.58TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.20% 1.53TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.37% 1.49TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+59.91% 1.48TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.35% 1.41TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A049960 Stock
  4. Financials Cell Biotech Co., Ltd.